Skip to main content

Table 1 Characteristics of patients according to BRAF status

From: Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

  Wild-type BRAF Mutated BRAF p
n = 33 n = 41
Demographic characteristics
 Median age at diagnosis, years [IQR] 59.4 [46.6–72.4] 51.3 [38.9–65.3] 0.10
 Gender, n (%)    0.32
  Male 23 (69.7) 24 (58.5)  
  Female 10 (30.3) 17 (41.5)  
Clinical characteristics
 ECOG-PS ≥1, n (%) 13 (39.4) 33 (80.5) < 0.001
 Brain metastasis at initial stage IV disease, n (%) 3 (9.1) 14 (34.1) 0.01
 Brain metastasis at first anti PD-1 administration, n (%) 6 (18.2) 25 (61.0) < 0.001
 Number of metastatic sites at anti PD-1 initiation    0.04
   ≤ 3, n (%) 16 (48.5) 17 (41.5)  
   > 3, n (%) 8 (24.2) 20 (48.8)  
 Elevated LDH before PD-1, n (%) 18 (54.5) 19 (46.3) 0.78
Tumor characteristics
 Known primary, n (%) 28 (84.8) 39 (95.1) 0.13
 Location of primary
  Head and neck, n (%) 3 (10.7) 8 (20.5)  
  Palms and soles, n (%) 5 (17.9) 0 (0)  
  Upper and lower extremities, n (%) 11 (39.3) 16 (41.0)  
  Trunk, n (%) 9 (32.1) 15 (38.5)  
Histopathological features
 Acrolentiginous melanoma, n (%) 7 (25.0) 0 (0)  
 Desmoplastic, n (%) 2 (7.1) 0 (0)  
 Nodular melanoma, n (%) 4 (14.3) 10 (25.6)  
 Superficial Spreading Melanoma, n (%) 13 (46.4) 23 (59.0)  
 Non classable, n (%) 2 (7.1) 4 (10.3)  
 Breslow index, mm [IQR] 3.6 [1.8–4.8] 3.0 [1.8–4.2] 0.52
 Ulceration, n (%) 16 (48.5) 17 (41.5) 0.04
 Sentinel lymph node status, n (%) 15 (45.5) 17 (41.5) 0.26
Treatment characteristics
 Number of lines of therapy before anti PD-1    0.12
  1, n (%) 21 (63.6) 36 (87.8)  
   ≥ 2, n (%) 12 (36.4) 5 (12.2)  
 Period of systemic therapy before anti PD-1, months [IQR] 3 [3–11.5] 9 [6–20.5] 0.007
 BRAF Inhibitor, n (%)   15 (36.6)  
 BRAF + MEK inhibitors, n (%)   26 (63.4)  
 Ipilimumab before anti PD-1, n (%) 31 (93.9) 5 (12.2)  
 Anti PD-1 therapy
  Nivolumab, n (%) 22 (66.7) 36 (87.8)  
  Pembrolizumab, n (%) 11 (33.3) 5 (12.2)  
Immune mediated toxicities, n (%) 15 (35.5) 4 (9.8) 0.003
 Cutaneous rash, n (%) 5 (38.5) 0 (0)  
 Diarrhea/enterocolitis, n (%) 1 (7.7) 2 (50)  
 Hepatitis, n (%) 2 (15.4) 0 (0)  
 Hypophysitis, n (%) 0 (0) 1 (25)  
 Lung toxicity, n (%) 3 (23.1) 1 (25)  
 Thyroiditis, n (%) 2 (15.4) 0 (0)  
 Vitiligo, n (%) 7 (46.7) 2 (50)  
 Other, n (%) 8 (61.5) 1 (25)  
  1. Continuous variables are described by median and interquartile range and categorical variables by number and proportion
  2. Abbreviations: ECOG-PS Eastern Cooperative Oncology Group Performance tatus, LDH lactate dehydrogenase, PD-1 programmed cell Death-1s